Barclays’s AVEO Pharmaceuticals, Inc. AVEO Stock Holding History

Barclays’s Portfolio AVEO Stock Details AVEO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-6,750	Closed	-$42K	–	6713
2019 Q4	$42K	Hold	6,750	–	–	﹤0.01%	5788
2019 Q3	$57K	Hold	6,750	–	–	﹤0.01%	5851
2019 Q2	$45K	Hold	6,750	–	–	﹤0.01%	6153
2019 Q1	$55K	Sell	6,750 -63,000	-90%	-$650K	﹤0.01%	5808
2018 Q4	$1.12M	Buy	69,750 +25,000	+56%	+$550K	﹤0.01%	2996
2018 Q3	$1.48M	Buy	44,750 +39,650	+777%	+$1.02M	﹤0.01%	3241
2018 Q2	$115K	Sell	5,100 -5,770	-53%	-$137K	﹤0.01%	5146
2018 Q1	$315K	Buy	+10,870	New	+$318K	﹤0.01%	4420

Barclays's AVEO Position: Q1 2023 in Review

Barclays sold out of AVEO Pharmaceuticals, Inc. (AVEO) in Q1 2023, closing a stake of 34,444 shares — an estimated $515K sold.

Barclays first reported a position in AVEO in Q2 2013 and held it in 17 quarters. The position peaked at $1.17M in Q3 2017. 0 funds tracked by Wall St. Rank hold AVEO as of Q1 2023.

Barclays reported no remaining AVEO Pharmaceuticals, Inc. position as of Q1 2023 after selling out during the quarter.
Barclays sold 34,444 AVEO Pharmaceuticals, Inc. shares in Q1 2023, an estimated $515K.
Barclays first reported a position in AVEO Pharmaceuticals, Inc. in Q2 2013 and held it in 17 quarters.
Barclays's AVEO Pharmaceuticals, Inc. position peaked at $1.17M in Q3 2017.
0 funds tracked by Wall St. Rank held AVEO Pharmaceuticals, Inc. as of Q1 2023.

Based on Barclays's 13F filing for Q1 2023, filed 4 May 2023.